A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

To join this study, you must have been diagnosed with multiple myeloma and it needs to be what doctors call 'measurable.' This means we can see evidence of the cancer through blood or urine tests. You should have already tried between one and three different treatments for your myeloma, including certain types of medicines like a 'proteasome inhibitor,' 'lenalidomide,' and an 'anti-CD38 antibody.' These previous treatments also need to have not worked for your cancer, or your cancer might have gotten worse after them.

There are also some things that would mean you couldn't take part. For example, if you've already had certain types of advanced cell therapies (like bispecific antibodies or CAR-T cell therapy), or if you have severe allergies to the study medicine. You also can't have had a live vaccine recently, and the cancer shouldn't have spread to your brain or spinal cord.

Women who could become pregnant would need to have specific pregnancy tests and agree to continue them during the study. Generally, participants must be at least 18 years old and be well enough to take part in a study, as assessed by a doctor.

If you join this study, it involves taking the medicine Teclistamab. You'll have regular hospital visits for assessments, which will include blood and urine tests to monitor your health and how the medicine is working. These tests will also help us understand how the new version of Teclistamab behaves in your body compared to the old one. There will likely be physical exams and other checks to make sure you're tolerating the treatment well. The total duration of your participation will depend on how you respond to the treatment and the study's requirements for follow-up.